JINGBAO LIU

Jingbao Liu has worked in various roles in the scientific field since 2012. In 2012, they worked as a Medicinal Chemist for Roche pRED (China), where they designed, synthesized, and evaluated novel HAPs-based anti-HBV agents. From 2013 to 2014, they were a Postdoctoral Scholar at the University of California, San Diego and the University of Connecticut, where they engineered proteins, expressed, purified, crystallized, and analyzed CYP 2B enzyme-ligand complexes to study structure and function in different species. In 2017, they worked as a Senior Scientist at ALSTEM, INC, where they generated genome edited iPSC cell lines using CRISPR-Cas9 technology and generated stable cell lines using lentivirus technology assisted with Flow Cytometry and/or Western Blot. Currently, they are a Research Scientist at Eureka Therapeutics, Inc, where they are responsible for antibody lead discovery via phage display technology, evaluating new antibodies for CAR/TCR-T cell therapy, and optimizing antibody-CAR/TCR platform to enhance efficacy, persistence, and reduce cytokine syndrome.

Jingbao Liu obtained a Doctor of Philosophy (Ph.D.) in Medicinal Chemistry from Shanghai Jiao Tong University between 2008 and 2013, advised by Prof. Lei Fu.